Project Grant R01DA045029

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $6,809,660 Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Pittsburgh to implement and personalize opioid-sparing pain management for major inpatient surgeries in children. The project aims to (a) investigate the efficacy and safety of a multidose methadone-based standardized enhanced recovery after surgery (ERAS) protocol, and (b) develop personalized ERAS...

This $779,969 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to improve perioperative care for patients with opioid use disorder. The grant will fund a 5-year study to prospectively capture patient-reported pain and opioid use among individuals with opioid use disorder undergoing common surgical procedures, and develop a clinical care pathway to optimize perioperative outcomes across a network of...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $598,312 to Addinex Technologies, Inc. to integrate and assess a closed-loop medication management system focused on opioid pain management for patients with extremity fractures being discharged from the emergency department. The system aims to reduce opioid use by integrating an opioid dispensing, monitoring, and disposal platform with a...

The National Institute on Drug Abuse (NIDA), through the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $23,579,701 Cooperative Agreement to Ensysce Biosciences, Inc. to continue the clinical development of PF614-MPAR, an opioid product with overdose protection. PF614-MPAR is a combination product that includes a trypsin-activated abuse-resistant oxycodone prodrug (PF614) and the trypsin inhibitor nafamostat, which provides overdose protection. The goal of this award is to...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $238,500 to the University of Pittsburgh to conduct a randomized, blinded clinical trial evaluating a telemedicine-delivered digital cognitive behavioral intervention (DCBI) to reduce postoperative opioid use among patients undergoing total knee and hip arthroplasty. The research aims to quantify the opioid-sparing effects of the DCBI, evaluate its...

This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is for a $1,837,542 project titled "Targeting Treatment-Resistant OUD with Ketamine-Assisted Mindfulness-Oriented Recovery Enhancement." The project aims to investigate the safety, preliminary efficacy, and psycho-physiological mechanisms of combining the psychotherapy Mindfulness-Oriented Recovery Enhancement (MORE) with ketamine...

This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,593,126 to Dimerx, Inc. to rigorously evaluate the safety and efficacy of their non-addictive, peripherally acting opioid analgesic compound DMX-101 through various preclinical and clinical phases. The key products and services to be delivered include: Assessing the abuse liability potential of DMX-101 in rats, demonstrating that it does...

This Cooperative Agreement award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the clinical development of SBS-147, a first-in-class oral arylepoxamide agonist for the treatment of pain. The $3,138,031 award to Sparian Biosciences Inc., doing business as Palion Therapeutics, aims to conduct a Phase 1 safety and tolerability study as well as a Phase 2a dental pain proof-of-concept trial for SBS-147. This novel...

The Auburn University Harrison College of Pharmacy Center for Opioid Research, Education, and Outreach (COACH) was awarded a $100,000 Project Grant by the Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) federal grant program. The project aims to host a series of three annual conferences focused on safe opioid use and harm reduction strategies for older adult, racial/ethnic minority, and LGBTQ+ populations, which are...

This $385,000 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to advance integrated treatment for co-occurring opioid use disorder (OUD) and alcohol use disorder (AUD) in real-world settings. The key objectives are to: Assess the effectiveness of integrated treatment approaches, including first-line medications and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), for patients with co-occurring OUD...